Using drugs to block myostatin can reduce the amount of muscle lost when a person is consuming fewer calories, by about half compared to not using such drugs.
See the scientific wording
Pharmacological inhibition of myostatin reduces muscle loss during caloric restriction by approximately 50% in humans.
Unverified — no studies directly back this
We haven't found enough studies to verify this claim yet.
Score breakdown, mechanism chain, raw evidence, ideal studies needed
Related videos
How Fit Body Science checks a claim
- 1
We isolate the claim
Health advice from videos, articles and studies is broken down into single, testable claims.
- 2
We find the research
Each claim is matched against peer-reviewed studies, with every source cited by DOI.
- 3
We grade the evidence
Studies are scored on methodology, statistical rigor, transparency and publication quality.
The fitness and health internet is full of confident claims. We check them against real research.
Every claim on this site is traced back to peer-reviewed studies, scored on methodology and reporting quality, and given a verdict you can audit yourself — sources, DOIs and all.
- Full evidence breakdown and mechanism chains
- Ask our AI anything about a claim or its studies
- Get notified when new research changes a verdict
Using drugs to block myostatin can reduce the amount of muscle lost when a person is consuming fewer calories, by about half compared to not using such drugs.
Evidence from Studies
No evidence studies found yet.
What Would Prove This
Per GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this claim, ordered from strongest to weakest.
Systematic Review of Pharmacological Myostatin Inhibitors on Muscle Mass Preservation During Caloric Restriction in Humans
Population: Adults undergoing controlled caloric restriction; Intervention: Pharmacological myostatin inhibitor; Comparator: Placebo; Outcome: Change in lean muscle mass measured by DEXA or MRI; Duration: Minimum 8 weeks; Inclusion: All randomized controlled trials with quantitative muscle mass outcomes.
Double-Blind, Placebo-Controlled Trial of Myostatin Inhibitor on Muscle Preservation During 12-Week Caloric Restriction in Healthy Adults
Population: Healthy adults aged 18–65; Intervention: Weekly intravenous myostatin inhibitor; Comparator: Saline placebo; Outcome: Change in lean body mass via DEXA at baseline and week 12; Duration: 12 weeks; Control: Caloric intake reduced by 30% in both groups.
Prospective Cohort Study of Myostatin Inhibitor Use and Muscle Mass Changes During Weight Loss in Humans
Population: Adults initiating caloric restriction for weight loss; Exposure: Use of myostatin inhibitor (prescribed or experimental); Comparator: Non-users; Outcome: Change in muscle mass over 6–12 months; Measurement: DEXA scans at baseline, 3, 6, and 12 months.
In Vitro Effects of Myostatin Inhibitors on Human Skeletal Muscle Cell Protein Degradation Under Simulated Caloric Restriction
Population: Human primary myotubes derived from skeletal muscle biopsies; Intervention: Myostatin inhibitor exposure; Comparator: Vehicle control; Outcome: Rate of ubiquitin-proteasome activity and myofibrillar protein degradation under low-glucose/low-amino acid conditions; Duration: 72 hours.
Effect of Myostatin Inhibition on Muscle Mass Preservation During Caloric Restriction in C57BL/6 Mice
Population: Adult C57BL/6 mice; Intervention: Systemic myostatin-blocking antibody; Comparator: IgG control; Outcome: Quadriceps and gastrocnemius muscle mass; Duration: 4 weeks of 30% caloric restriction; Measurement: Wet weight and histology.